MetLife Investment Management’s Editas Medicine EDIT Stock Holding History

MetLife Investment Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$182K	Buy	56,216 +13,783	+32%	+$40.3K	﹤0.01%	2469
2026 Q1	$105K	Buy	42,433 +25,411	+149%	+$53.8K	﹤0.01%	2520
2025 Q4	$34.9K	Sell	17,022 -21,495	-56%	-$62.1K	﹤0.01%	2750
2025 Q3	$134K	Sell	38,517 -13,438	-26%	-$37.5K	﹤0.01%	2521
2025 Q2	$114K	Buy	+51,955	New	+$85K	﹤0.01%	2470
2024 Q4	–	Sell	-29,518	Closed	-$101K	–	2825
2024 Q3	$101K	Sell	29,518 -17,737	-38%	-$77.2K	﹤0.01%	2626
2024 Q2	$221K	Buy	47,255 +8,699	+23%	+$49.1K	﹤0.01%	2178
2024 Q1	$286K	Sell	38,556 -5,035	-12%	-$41.8K	﹤0.01%	1981
2023 Q4	$442K	Hold	43,591	–	–	﹤0.01%	1767
2023 Q3	$340K	Buy	43,591 +6,443	+17%	+$55.3K	﹤0.01%	1863
2023 Q2	$306K	Hold	37,148	–	–	﹤0.01%	2004
2023 Q1	$269K	Hold	37,148	–	–	﹤0.01%	2043
2022 Q4	$330K	Hold	37,148	–	–	﹤0.01%	1907
2022 Q3	$455K	Hold	37,148	–	–	﹤0.01%	1708
2022 Q2	$439K	Hold	37,148	–	–	﹤0.01%	1754
2022 Q1	$707K	Buy	37,148 +13,546	+57%	+$252K	﹤0.01%	1560
2021 Q4	$627K	Hold	23,602	–	–	0.01%	1389
2021 Q3	$970K	Sell	23,602 -1,346	-5%	-$73.8K	0.01%	1130
2021 Q2	$1.41M	Hold	24,948	–	–	0.01%	1003
2021 Q1	$1.05M	Hold	24,948	–	–	0.01%	1132
2020 Q4	$1.75M	Sell	24,948 -1,721	-6%	-$70.7K	0.02%	892
2020 Q3	$748K	Buy	26,669 +1,917	+8%	+$62.4K	0.01%	1171
2020 Q2	$732K	Buy	24,752 +3,234	+15%	+$84.5K	0.01%	1174
2020 Q1	$427K	Hold	21,518	–	–	0.01%	1297
2019 Q4	$637K	Hold	21,518	–	–	0.01%	1320
2019 Q3	$489K	Sell	21,518 -3,734	-15%	-$92.5K	0.01%	1434
2019 Q2	$625K	Sell	25,252 -38,240	-60%	-$913K	0.01%	1352
2019 Q1	$1.55M	Buy	63,492 +42,328	+200%	+$958K	﹤0.01%	1404
2018 Q4	$481K	Hold	21,164	–	–	0.01%	1393
2018 Q3	$673K	Hold	21,164	–	–	0.01%	1344
2018 Q2	$758K	Buy	21,164 +4,611	+28%	+$163K	0.01%	1160
2018 Q1	$549K	Hold	16,553	–	–	0.01%	1316
2017 Q4	$509K	Buy	+16,553	New	+$417K	0.01%	1383

Other funds holding EDIT

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

MetLife Investment Management's EDIT Position: Q2 2026 in Review

MetLife Investment Management increased its Editas Medicine (EDIT) stake by 32% in Q2 2026, buying an estimated $40.3K and bringing the position to 56,216 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

MetLife Investment Management first reported a position in EDIT in Q4 2017 and has held it in 33 quarters since. The position peaked at $1.75M in Q4 2020. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

MetLife Investment Management held 56,216 shares of Editas Medicine worth $182K as of Q2 2026.
MetLife Investment Management bought 13,783 Editas Medicine shares in Q2 2026, an estimated $40.3K.
Editas Medicine made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2469 holding.
MetLife Investment Management first reported a position in Editas Medicine in Q4 2017 and has held it in 33 quarters since.
MetLife Investment Management's Editas Medicine position peaked at $1.75M in Q4 2020.
214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.